AR106849A1 - Compuestos de bis-piridazina y su uso en el tratamiento del cáncer - Google Patents

Compuestos de bis-piridazina y su uso en el tratamiento del cáncer

Info

Publication number
AR106849A1
AR106849A1 ARP160103650A ARP160103650A AR106849A1 AR 106849 A1 AR106849 A1 AR 106849A1 AR P160103650 A ARP160103650 A AR P160103650A AR P160103650 A ARP160103650 A AR P160103650A AR 106849 A1 AR106849 A1 AR 106849A1
Authority
AR
Argentina
Prior art keywords
piridazine
bis
compounds
cancer treatment
hydro
Prior art date
Application number
ARP160103650A
Other languages
English (en)
Inventor
Raymond Verschoyle Finlay Maurice
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of AR106849A1 publication Critical patent/AR106849A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico, en donde: R¹ puede ser hidro, metoxi, difluorometoxi o trifluorometoxi; R² puede ser hidro, metoxi, trifluorometoxi o trifluorometilo; y R³ puede ser hidro o metoxi. El compuesto de la fórmula (1) puede inhibir la glutaminasa, por ejemplo, la GLS1.
ARP160103650A 2015-11-27 2016-11-29 Compuestos de bis-piridazina y su uso en el tratamiento del cáncer AR106849A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
AR106849A1 true AR106849A1 (es) 2018-02-21

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103650A AR106849A1 (es) 2015-11-27 2016-11-29 Compuestos de bis-piridazina y su uso en el tratamiento del cáncer

Country Status (17)

Country Link
US (2) US10196382B2 (es)
EP (1) EP3380468B8 (es)
JP (1) JP2018535226A (es)
KR (1) KR20180083426A (es)
CN (1) CN108349951B (es)
AR (1) AR106849A1 (es)
AU (1) AU2016360970B2 (es)
CA (1) CA3005102A1 (es)
DK (1) DK3380468T3 (es)
ES (1) ES2806723T3 (es)
GB (1) GB201520959D0 (es)
IL (1) IL259358A (es)
MX (1) MX2018006374A (es)
RU (1) RU2018122012A (es)
SG (1) SG11201803814SA (es)
TW (1) TW201731837A (es)
WO (1) WO2017089587A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106552296B (zh) 2015-09-29 2020-08-14 上海氪励铵勤科技发展有限公司 纳米粒子、其制备方法与结石取出装置及应用
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6031527B2 (ja) 2011-11-21 2016-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼのヘテロ環式阻害剤
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US9783533B2 (en) 2014-01-06 2017-10-10 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201730188A (zh) 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
AU2016360970A1 (en) 2018-07-05
KR20180083426A (ko) 2018-07-20
TW201731837A (zh) 2017-09-16
WO2017089587A1 (en) 2017-06-01
JP2018535226A (ja) 2018-11-29
DK3380468T3 (da) 2020-07-27
IL259358A (en) 2018-07-31
EP3380468B8 (en) 2020-11-04
ES2806723T3 (es) 2021-02-18
CA3005102A1 (en) 2017-06-01
AU2016360970B2 (en) 2019-11-07
SG11201803814SA (en) 2018-06-28
CN108349951B (zh) 2020-11-13
GB201520959D0 (en) 2016-01-13
US20170152244A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
US10196382B2 (en) 2019-02-05
EP3380468B1 (en) 2020-05-20
EP3380468A1 (en) 2018-10-03
RU2018122012A (ru) 2019-12-30
US20190169172A1 (en) 2019-06-06
CN108349951A (zh) 2018-07-31
US10577354B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
ECSP17054980A (es) Inhibidores selectivos de bace1
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MD3395821T2 (ro) Compuși antitumorali
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR106875A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
AR112346A1 (es) Derivados de [1,2,4]triazolo
CL2019000229A1 (es) Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida.
CO2017007940A2 (es) Péptidos antagonistas prgc
AR115865A2 (es) Compuestos terapéuticos
AR108363A1 (es) Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos
BR112018012326A2 (pt) composto de fenilimidazol
AR105924A1 (es) Compuestos terapéuticos y síntesis

Legal Events

Date Code Title Description
FB Suspension of granting procedure